#072: Natalizumab (Tysabri, Tyruko) for active relapsing remitting MS

#072: Natalizumab (Tysabri, Tyruko) for active relapsing remitting MS

Natalizumab (Tysabri, Tyruko) is approved as disease-modifying therapy (DMT) for active RRMS with a rapidly evolving severe MS.

You can read the complete article on my blog: https://ms-perspektive.com/072-natalizumab

Today we are talking about natalizumab, which is known under the trade names Tysabri and Tyruko. The immunotherapy is used for active, severe courses of relapsing forms of MS.

Natalizumab is a migration-inhibiting drug that prevents the migration of T and B cells into the central nervous system.

Please remember that I can only provide an overview here. Your neurologist and your MS nurse should give you detailed advice on choosing the right therapy for you. This is because they know your overall state of health and you should also talk about your goals, wishes, fears and preferences so that these can be taken into account.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(193)

#191: BTK inhibitors in MS: where do we stand after ECTRIMS/ACTRIMS 2026?

#191: BTK inhibitors in MS: where do we stand after ECTRIMS/ACTRIMS 2026?

BTK inhibitors have produced different results in multiple sclerosis trials. In episode no. 191, I explore what we learned at ECTRIMS/ACTRIMS 2026 about individual medicines, their potential benefits ...

11 Nov 19min

#190: Living with multiple sclerosis. Gabriela's story and the "(un)seen faces of MS" Art Project

#190: Living with multiple sclerosis. Gabriela's story and the "(un)seen faces of MS" Art Project

https://ms-perspektive.de/en/190-unseen-faces-of-ms/Living with multiple sclerosis often means experiencing symptoms that others cannot see. Austrian artist Gabriela Romagna shares her journey to an M...

4 Nov 32min

#189: New imaging in MS: understanding progression and finding better treatments | ECTRIMS 2026

#189: New imaging in MS: understanding progression and finding better treatments | ECTRIMS 2026

How could new imaging in MS help us understand progression and develop better treatments? In this episode, I explore key insights from Daniel Reich's MSToronto2026 lecture and related research. Learn ...

28 Okt 15min

#188: Jan Van Amstel on EMSP's Four-Year Presidency and the Future of MS Advocacy in Europe

#188: Jan Van Amstel on EMSP's Four-Year Presidency and the Future of MS Advocacy in Europe

"Get rid of MS as soon as possible and make ourselves superfluous." — Jan van Amstel What can a stronger European voice achieve for people living with MS? In episode #188, EMSP President Jan van Amste...

21 Okt 31min

#187: Aging in multiple sclerosis: relapses, progression and treatment choices with Dr. Yi Chao Foong

#187: Aging in multiple sclerosis: relapses, progression and treatment choices with Dr. Yi Chao Foong

Aging in multiple sclerosis brings new questions about relapses, gradual progression and treatment choices. In episode 187, Dr. Yi Chao Foong, an MS neurologist and researcher in Tasmania, explains wh...

14 Okt 29min

#186: Protecting nerve cells in multiple sclerosis: A new path toward neuroprotection with Prof. Manuel Friese

#186: Protecting nerve cells in multiple sclerosis: A new path toward neuroprotection with Prof. Manuel Friese

Why can multiple sclerosis progress even when relapses are well controlled? In episode 186, I speak with Prof. Manuel Friese about the next challenge in MS research: protecting nerve cells from damage...

7 Okt 43min

#185: Living with MS in Mexico – who gets diagnosed, who gets treated, and who gets left behind?

#185: Living with MS in Mexico – who gets diagnosed, who gets treated, and who gets left behind?

An MS diagnosis can depend on where you live, whether you can reach a neurologist and how quickly you can get an MRI. In this episode, Nele speaks with neurologist and neuroimmunologist Dr. Enrique Go...

30 Sep 36min

#184: MS treatment across the disease course – treat early, think long-term, don't give up too soon with Prof. Klaus Schmierer

#184: MS treatment across the disease course – treat early, think long-term, don't give up too soon with Prof. Klaus Schmierer

Read the full blog post and interview here: https://ms-perspektive.de/en/184-klaus-schmierer/ How early should MS treatment start, how strongly should we treat, and is there ever a point when it becom...

23 Sep 41min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
fryktlos
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-strid
foreldreradet
treningspodden
rss-bisarr-historie
rss-ekteskapet
jakt-og-fiskepodden
rss-kunsten-a-leve
rss-kull
mikkels-paskenotter
rss-orjasater
sinnsyn
gravid-uke-for-uke
rss-flydilla
rss-mind-body-podden
hverdagspsyken
branncast